Predictive significance of KRAS point mutation in patients with non-small cell lung carcinoma relation to smoking and asbestos exposure in middle Anatolia population

被引:0
作者
Arslan, Sulhattin [1 ]
Akkurt, Ibrahim [1 ]
Koksal, Binnur [2 ]
Karadayi, Sule [3 ]
Ozdemir, Ozturk [2 ]
机构
[1] Cumhuriyet Univ, Fac Med, Dept Chest Dis, Sivas, Turkey
[2] Cumhuriyet Univ, Fac Med, Dept Med Genet, Sivas, Turkey
[3] Cumhuriyet Univ, Fac Med, Dept Emergency, Sivas, Turkey
来源
HEALTHMED | 2010年 / 4卷 / 04期
关键词
NSCLC; KRAS mutation; smoke and asbestos exposure; K-RAS; EGFR; ADENOCARCINOMA; THERAPY; PROFILE; TUMORS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Persons who have been occupationally exposed to environmental mutagens have a substantially increased risk for somatic oncogene mutations. Structural mutation in viral kristen rat sarcoma oncogene homolog 2 (KRAS; v-Ki-ras 2) has been assessed as a mechanism of de-novo resistance to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibition in patients with non-small-cell lung cancer (NSCLC). The aim of the current study was to investigate the predictive significance of KRAS mutations in patient with NSCLC in relation to cigarette smoking and asbestos exposure. We have investigated 42 fresh tumoral tissue samples of cases that were histopathologically diagnosed as lung carcinomas. Patients were evaluated for clinical findings; tumoral tissue samples were examined histopathologically and genomic DNA from tumoral tissue samples were isolated. The KRAS point mutations were assessed by strip-Assay reverse hybridization method and compared with the healthy controls. A total of 24 patients (57%) demonstrated KRAS point mutations in their tumoral tissues, while 18 (43%) patients did not. Mutations were accumulated in current cases of NSCLC, which were active smokers and exposed to the asbestos. Current results showed that the combined effects of somatic mutations in KRAS may play an active role in development of primary lung carcinomas due to heavy smoke and asbestos exposure. Results also may have important implications for molecular diagnosis and targeted therapies in NSCLC.
引用
收藏
页码:715 / 719
页数:5
相关论文
共 17 条
[1]  
[Anonymous], CENC RES
[2]   A Gene-Alteration Profile of Human Lung Cancer Cell Lines [J].
Blanco, Raquel ;
Iwakawa, Reika ;
Tang, Moying ;
Kohno, Takashi ;
Angulo, Barbara ;
Pio, Ruben ;
Montuenga, Luis M. ;
Minna, John D. ;
Yokota, Jun ;
Sanchez-Cespedes, Montse .
HUMAN MUTATION, 2009, 30 (08) :1199-1206
[3]   Ultrastructural and molecular heterogeneity in non-small cell lung carcinomas:: Study of 110 cases and review of the literature [J].
Bombi, JA ;
Martínez, A ;
Ramírez, J ;
Grau, JJ ;
Nadal, A ;
Fernández, PL ;
Palacín, A ;
Cardesa, A .
ULTRASTRUCTURAL PATHOLOGY, 2002, 26 (04) :211-218
[4]   DOSE-DEPENDENT RAS MUTATION SPECTRA IN N-NITROSODIETHYLAMINE INDUCED MOUSE-LIVER TUMORS AND 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE INDUCED MOUSE LUNG-TUMORS [J].
CHEN, B ;
LIU, L ;
CASTONGUAY, A ;
MARONPOT, RR ;
ANDERSON, MW ;
YOU, M .
CARCINOGENESIS, 1993, 14 (08) :1603-1608
[5]  
Feng ZH, 2002, J NATL CANCER I, V94, P1527
[6]   Origin and prognostic value of circulating KRAS mutations in lung cancer patients [J].
Gautschi, O. ;
Huegli, B. ;
Ziegler, A. ;
Gugger, M. ;
Heighway, J. ;
Ratschiller, D. ;
Mack, P. C. ;
Gumerlock, P. H. ;
Kung, H. J. ;
Stahel, R. A. ;
Gandara, D. R. ;
Betticher, D. C. .
CANCER LETTERS, 2007, 254 (02) :265-273
[7]   EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy [J].
Italiano, Antoine ;
Cortot, Alexis B. ;
Ilie, Marius ;
Martel-Planche, Ghyslaine ;
Fabas, Thibault ;
Pop, Daniel ;
Mourux, Jerome ;
Hofman, Veronique ;
Hofman, Paul ;
Pedeutour, Florence .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (10) :2479-2482
[8]   Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC [J].
Kalikaki, A. ;
Koutsopoulos, A. ;
Trypaki, M. ;
Souglakos, J. ;
Stathopoulos, E. ;
Georgoulias, V. ;
Mavroudis, D. ;
Voutsina, A. .
BRITISH JOURNAL OF CANCER, 2008, 99 (06) :923-929
[9]   The Kras2 oncogene and mouse lung carcinogenesis [J].
Lee, Gang-Hong .
MEDICAL MOLECULAR MORPHOLOGY, 2008, 41 (04) :199-203
[10]  
Mehic B, 2009, HEALTHMED, V3, P3